We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Incisionless Surgery Shows Promise in Prostate Cancer Treatment

By HospiMedica International staff writers
Posted on 16 Aug 2010
A new surgical procedure for the treatment of prostate cancer uses surgical instruments inserted through the penis, signaling the next step in the evolution of minimally invasive surgery. More...


Researchers at the Mayo Clinic (Scottsdale, AZ, USA) have developed special tools to allow natural orifice transluminal endoscopic surgical (NOTES) removal of the prostate, naming the procedure NOTES radical prostatectomy (NOTES RP). The instruments are inserted through the urethra, and an innovative technique is used to remove the entire prostate. Surgeons then rejoin the internal tissues via specialized instruments that are also designed to work through the urethra. Patients benefit from the procedure because there are no incisions, little risk of bleeding, and are usually able to leave the hospital within 24 hours.

The procedure involves a 100 W holmium:yttrium-aluminum-garnet laser with a 550 μm end-firing laser fiber, a 26F resectoscope, a 7F laser stabilizing catheter, and continuous irrigation. The surgeons first radically resect the prostate with the lasers; the tissue is then removed endoscopically with a tissue morcellator and delivered into the bladder. The first patient to undergo the NOTES RP procedure at the Mayo Clinic was released in June 2010, and suffered no complications throughout any part of the operation.

"The reason this hasn't been done in prostate surgery before is because of the challenge of rejoining or suturing the bladder back to the urethra,” said urologist Mitchell Humphreys, M.D., of the Mayo Clinic. "This really shows that the impossible is now possible, and represents a paradigm shift not only in the way we look at diseases, but also how we surgically treat disease.”

Standard surgical therapy for prostate cancer--one of the most commonly diagnosed malignancies in men--involves removal of the prostate through open, laparoscopic, or robot-assisted laparoscopic means. Each of these approaches involves removes the entire prostate, and presumably the cancer, and then suturing the bladder back to the urethra to restore the continuity of the urinary system.

Related Links:
Mayo Clinic


Gold Member
12-Channel ECG
CM1200B
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Surgical Headlight
IsoTorch
Mammography System (Analog)
MAM VENUS
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.